Tag: equity
-
Synthetic Bio Chemicals Start-Up Gains $5M in Early Funds
A new enterprise using digital and synthetic biology to create sustainable chemicals at industrial scale is raising $5 million in pre-seed round funds.
-
Immune Disease Biotech Acquired in $405M Deal
A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences.
-
Biotech Start-Up Demonstrates Cancer Therapy, Raises $6.4M
A new biotechnology company demonstrated in lab mice its therapy for glioblastoma, an aggressive brain cancer, that overcomes limitations of current treatments.
-
Biotechs Discover Antimicrobial Peptide for Food Safety
Two biotechnology companies say they discovered a peptide molecule with antimicrobial properties for faster identification and containment of food contamination outbreaks.
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Infographic – Digital Health Keeps Clicking in 2022
While venture capital funding for digital health start-ups worldwide is down compared to last year, the pace so far in 2022 remains on an historically strong track.
-
Synthetic Bio Microbiome Biotech Gains $15M in Seed Funds
A developer of therapies produced with synthetic biology for diseases linked to microbes in the gut is raising $15 million in seed financing.
-
Surgical Robotics Company Raises $55M in Early Funds
A developer of robotic systems for cataract and other eye surgeries is raising $55 million in its first venture financing round.
-
Infographic – US Biotech Investments Stay Strong
The first half half of 2022 shows venture investments in U.S. biotechnology start-ups cooled from the blistering pace of last year, but biotech remains a robust sector.
-
Precision Protein Design Start-Up Gains $40M in Early Funds
A start-up company designing and testing precise proteins within live animals to speed creation of new therapeutics is raising $40 million in its first venture round.